Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Targeted BEACOPP in Advanced Classical Hodgkin Lymphoma
NCT01569204Phase 2Completed
- Sponsor
- University of Cologne
- Start
- Oct 2012
- Primary completion
- Mar 2014
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of brentuximab vedotin in classical Hodgkin lymphoma (cHL) (2 arms), sponsored by University of Cologne. Primary endpoints: Response Rate at 18 weeks and Complete Remission Rate at 18 weeks. Started Oct 2012; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT01569204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01569204.